Primary central nervous system lymphoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:46135C83.3
Who is this for?
Show terms as
71Active trials77Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

PCNSLPrimary CNS lymphomaPrimary brain lymphoma
Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Apr 2026Methotrexate Early Toxicity Monitoring

Assistance Publique Hopitaux De Marseille — NA

TrialNOT YET RECRUITING
Mar 2026IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Ono Pharmaceutical Co. Ltd — PHASE3

TrialRECRUITING
Feb 2026Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

Zhejiang Cancer Hospital — PHASE2

TrialRECRUITING
Feb 2026PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL.

The First Affiliated Hospital with Nanjing Medical University — PHASE2

TrialRECRUITING
Jan 2026Zillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma

Ruijin Hospital — PHASE2

TrialNOT YET RECRUITING
Dec 2025A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

Tongji Hospital — PHASE2

TrialRECRUITING
Nov 2025Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

Hyungwoo Cho — PHASE2

TrialRECRUITING
Nov 2025A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company — PHASE2

TrialRECRUITING
Oct 2025Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

Huashan Hospital — PHASE2, PHASE3

TrialNOT YET RECRUITING
Sep 2025Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

The Lymphoma Academic Research Organisation — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Primary central nervous system lymphoma.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →
Phase 33 trials
OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma
Phase 3
Active
PI: Gerald Illerhaus, Prof (Klinikum Stuttgart) · Sites: Stuttgart, Baden-Wurttemberg · Age: 18–70 yrs
View on ClinicalTrials.gov ↗I'm interested →
Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients
Phase 3
Actively Recruiting
· Sites: Freiburg im Breisgau, Baden-Wurttemberg; Stuttgart, Baden-Wurttemberg +33 more · Age: 65–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Phase 3
Actively Recruiting
PI: Clinical Team (Deciphera Pharmaceuticals, LLC) · Sites: Scottsdale, Arizona; New Haven, Connecticut +2 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 41 trial
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Phase 4
Actively Recruiting
· Sites: Moscow, RF · Age: 0–18 yrs
View on ClinicalTrials.gov ↗I'm interested →
Phase 26 trials
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.
Phase 2
Actively Recruiting
PI: Seok Jin Kim, MD, PhD (Samsung Medical Center) · Sites: Seoul · Age: 19–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
Phase 2
Actively Recruiting
PI: Haiyan Yang, MD (Zhejiang Cancer Hospital) · Sites: Hangzhou, Zhejiang · Age: 18–80 yrs
View on ClinicalTrials.gov ↗I'm interested →
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma
Phase 2
Actively Recruiting
· Sites: Seongnam-si, Please Select · Age: 19–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
Phase 2
Actively Recruiting
PI: Prakash Ambady, MD (Providence Health & Services) · Sites: New York, New York; Cleveland, Ohio +5 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab
Phase 2
Actively Recruiting
PI: Hervé Pr. Ghesquieres, MD (HCL - Hôpital Lyon Sud - Service d'Hématologie - 1) · Sites: Bordeaux; Caen +11 more · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL
Phase 2
Actively Recruiting
· Sites: Moscow · Age: 18–70 yrs
View on ClinicalTrials.gov ↗I'm interested →
Other8 trials
Secondary Central Nervous System Lymphoma Registry - Charité
Actively Recruiting
· Sites: Berlin
View on ClinicalTrials.gov ↗I'm interested →
Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Actively Recruiting
· Sites: Fuzhou, Fujian · Age: 18–75 yrs
View on ClinicalTrials.gov ↗I'm interested →
CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)
Actively Recruiting
· Sites: Helsinki; Kuopio +3 more · Age: 18–70 yrs
View on ClinicalTrials.gov ↗I'm interested →
MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway
Active
PI: Bent Indredavik, PhD Prof (Norwegian University of Science and Technology) · Sites: Ålesund; Kristiansund +6 more · Age: 18–90 yrs
View on ClinicalTrials.gov ↗I'm interested →
Prospective Neurobehavioral Functions in Newly-diagnosed Patients With Primary CNS Lymphoma Treated With Hyperfractionated Conformal Whole-brain Radiation Therapy Plus Simultaneous Integrated Boost
Actively Recruiting
· Sites: Taoyuan District · Age: 18–80 yrs
View on ClinicalTrials.gov ↗I'm interested →
Real World Data on Ibrutinib Use in PCNSL Rel/Ref
Active
· Sites: Milan, Italy · Age: 18–80 yrs
View on ClinicalTrials.gov ↗I'm interested →
CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
Actively Recruiting
PI: Ian Chau (Royal Marsden NHS Foundation Trust) · Sites: Sutton · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →
Improving Safety and Accuracy of Stereotactic Brain Biopsies in Primary Central Nervous System Lymphoma.
Actively Recruiting
PI: Pietro Mortini, MD, Prof. (IRCCS San Raffaele Scientific Institute) · Sites: Milan, Milan · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

Showing 25 of 77View all specialists →
NM
Narendranath Epperla, MD, MS
COLUMBUS, OH
Specialist
PI on 2 active trials2 Primary central nervous system lymphoma publications
CD
Christopher Dittus
CHAPEL HILL, NC
Specialist
PI on 1 active trial1 Primary central nervous system lymphoma publication
AP
Aurélie KAS, Pr
Specialist
PI on 1 active trial
WL
Wenbin Li
Specialist
PI on 3 active trials628 Primary central nervous system lymphoma publications
CM
Christian Grommes, MD
NEW YORK, NY
Specialist
PI on 8 active trials
PL
Project Leader
Specialist
PI on 11 active trials
TM
Tracy Batchelor, MD, MPH
BOSTON, MA
Specialist
PI on 5 active trials
MM
Mitchell S Cairo, MD
HAWTHORNE, NY
Specialist
PI on 12 active trials
AM
Antonio Omuro, MD
STANFORD, CA
Specialist
PI on 3 active trials1 Primary central nervous system lymphoma publication
SP
Stanislaw R. Burzynski, MD, PhD
HOUSTON, TX
Specialist
PI on 29 active trials
MI
Meredith S Irwin
CINCINNATI, OH
Specialist
PI on 1 active trial
ZP
Zhihua Yao, M.D. Ph.D
Specialist
PI on 3 active trials
YP
Yanyan Liu, M.D. Ph.D
Specialist
PI on 3 active trials
RM
Rahul Lakhotia, M.D.
WASHINGTON, DC
Specialist
PI on 4 active trials
JM
Jana Portnow, MD
DUARTE, CA
Specialist
PI on 3 active trials
NM
Neha Mehta-Shah, M.D.
SAINT LOUIS, MO
Specialist
PI on 4 active trials
LM
Lauren E. Abrey, MD
NEW YORK, NY
Specialist
PI on 6 active trials1 Primary central nervous system lymphoma publication
TS
Tanya Siddiqi
DUARTE, CA
Specialist
PI on 3 active trials10 Primary central nervous system lymphoma publications
MM
Mark J Roschewski, M.D.
WASHINGTON, DC
Specialist
PI on 6 active trials
HT
Han Tun
JACKSONVILLE, FL
Specialist
PI on 2 active trials2 Primary central nervous system lymphoma publications
JP
James L. Rubenstein, MD, PhD
Specialist
PI on 2 active trials
SK
Shaji Kumar
Anchorage, Alaska
Specialist

Rare Disease Specialist

PI on 7 active trials
AW
Ann Woolfrey
SEATTLE, WA
Specialist
PI on 5 active trials
AT
Amanda M Termuhlen
MINNEAPOLIS, MN
Specialist
PI on 1 active trial1 Primary central nervous system lymphoma publication
LM
Lauren Schaff, MD
AMBLER, PA
Specialist
PI on 1 active trial1 Primary central nervous system lymphoma publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Primary central nervous system lymphoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Primary central nervous system lymphomaForum →

No community posts yet. Be the first to share your experience with Primary central nervous system lymphoma.

Start the conversation →

Latest news about Primary central nervous system lymphoma

Disease timeline:

New recruiting trial: Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

New recruiting trial: The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

A new clinical trial is recruiting patients for Primary central nervous system lymphoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Primary central nervous system lymphoma

Are there clinical trials for Primary central nervous system lymphoma?

Yes — 20 recruiting clinical trials are currently listed for Primary central nervous system lymphoma on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Primary central nervous system lymphoma?

25 specialists and care centers treating Primary central nervous system lymphoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.